ANROのROE（自己資本利益率）は？

ALTO NEUROSCIENCE, INC.のROEは-30.53%です。

ANROの配当利回りは？

ALTO NEUROSCIENCE, INC.の配当利回りは0.00%です。

ANROの品質スコア（Quality Score）は？

当社のAIはANROの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

ANROは今が買い時ですか？

当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

ANROはどのセクターに属しますか？

ALTO NEUROSCIENCE, INC.はHealthcare >> Biotechnologyセクターに分類されます（NYSE市場）

ANRO (NYSE) 株価分析 | ALTO NEUROSCIENCE, INC.

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ANRO AI Analysis Summary

Our AI summary for ANRO: ALTO NEUROSCIENCE, INC. (NYSE), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -30.53%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ANRO

ALTO NEUROSCIENCE, INC.

US:NYSE STOCK Healthcare >> Biotechnology News 65

USD 27.07

-1.56 (-5.45%) Day Change

Watchlist Portfolio Compare Chart

0.08

D/E

-30.5%

ROE

-26.9%

ROA

0.00%

Div Yield

ALTO NEUROSCIENCE, INC.
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 27.07 Price -1.56 (-5.45%) Day Change	NEWS SCORE: 65

ANRO, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) but テクニカルスコアは ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Deepscope 分析

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	65
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	27.07
PBV / Sector	4.13 / 5.20
Earning Per Share	-2.00

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	14.38 M GREAT
Average 1W Daily Value	9.08 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	N/A / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-26.90 / 27.02
ROA Average (%) / Sector	-38.43 / -368.17
ROA Change Average (%) / Sector	-15.75 / 5,404.12
ROE (%) / Sector	-30.53 / 3.47
ROE Average (%) / Sector	1.97 / 6.51
ROE Change Average (%) / Sector	-58.43 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

登録情報

Analyze Date	2026-08-01 07:59:28
Symbol	ANRO
Name	ALTO NEUROSCIENCE, INC.
Sector	Healthcare >> Biotechnology
Market	NYSE
Listed Shares	35.09 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,004.74 / 9,903.94

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 650 Castro Street, Mountain View, CA, United States, 94041

Phone: 650 200 0412

Website: https://www.altoneuroscience.com

Employees: 68

Sector: Healthcare >> Biotechnology

Description: Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.